Marco Serafini

Marco Serafini

Auto-generated profile, based on publicly available information

Marco Serafini

Research Institutes for Medicines (iMed), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in ChemMedChem
Verified
Journal Article
Closed access
ACAndré Campaniço
André Campaniço
SHShrika Harjivan
Shrika Harjivan
EFElisabete Freitas
Elisabete Freitas
MSMarco Serafini
Marco Serafini
Maria Manuela GasparMaria Manuela Gaspar
Maria Manuela Gaspar
FLFrancisca Lopes
Francisca Lopes

25 March 2026 in Chimia
Verified
Journal Article
Open access
PDF file
MSMarco Serafini
Marco Serafini
RMRui Moreira
Rui Moreira
AKT is a critical mediator of the phosphoinositide 3-kinase (PI3K) signalling cascade, playing a key role in regulating essential cellular processes. The identification of AKT as one of the most dysregulated pathways in cancer led to the development of multiple classes of inhibitors. Despite numerous inhibitors entering clinical investigation and leading to the FDA approval of Capivasertib, an ATP-competitive AKT inhibitor, in November 2023, AKT modulation through inhibition was characterised by toxicity and poor clinical efficacy. Targeted Protein Degradation (TPD) spearheaded by PROTACs boasted a paradigmatic shift in drug discovery and was demonstrated to be a valid therapeutic alternative to modulate AKT. To date, numerous AKT-targeting PROTACs have been disclosed. The majority of them outperformed the inhibitors in suppressing AKT activity, nurturing higher potency and improved selectivity. Notably, enhanced antiproliferative effects, sustained by more robust and prolonged inactivation of the AKT downstream signalling was observed. This review highlights AKT as a central therapeutic target in oncology and focuses on AKT modulation through a targeted protein degradation approach mainly using PROTACs. The review aims at illustrating all the AKT-targeting PROTACs disclosed in literature to date, a powerful new pharmacological tool that might remarkably expand the scope of AKT-targeted therapies and further elucidate the role of AKT in both normal and cancer-related phenotypes.